Safety, Tolerability, and Efficacy of Pirfenidone in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
Lancet Respir Med 2022 Sep 02;[EPub Ahead of Print], JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz, R Maurer, I Glaspole, PF Dellaripa, B Gooptu, R Vassallo, PG Cox, KR Flaherty, HI Adamali, MA Gibbons, L Troy, IA Forrest, JA Lasky, LG Spencer, J Golden, MB Scholand, N Chaudhuri, MA Perrella, DA Lynch, DC Chambers, M Kolb, C Spino, G Raghu, HJ Goldberg, IO RosasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.